Wednesday 20 November 2013
MIR: a trial of mirtazapine for treatment resistant depression
Centre for Academic Mental Health
Dr David Kessler - University of Bristol.
OS6 Seminar Room, Oakfield House, Oakfield Grove, Bristol, BS8 2BN,
MIR is a double blind placebo-controlled randomised trial of the addition of the antidepressant mirtazapine for patients with depression in primary care who have not responded to at least 6 weeks of treatment with a selective serotonin reuptake inhibitor or serotonin and noradrenaline reuptake inhibitor.